

## References

- Altice, F.L., Friedland, G.H., Cooney, E.L. (1999). Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. *AIDS*, 13(8), 957-962.
- Antoniou, T., Tseng, A.L. (2002). Interactions between recreational drugs and antiretroviral agents. *Annals of Pharmacotherapy*, 36(10), 1598-1613.
- Arnsten, J.H., Demas, P.A., Farzadegan, H., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. *Clinical Infectious Diseases*, 33(8), 1417-1423.
- Arnsten, J.H., Demas, P.A., Grant, R.W., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. *Journal of General Internal Medicine*, 17(5), 377-381.
- Bagasra, O., Pomerantz, R.J. (1993). Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. *Journal of Infectious Diseases*, 168(5), 1157-1164.
- Bamberger, J., Bangsberg, D., Chamber, D., et al. (June 2000). Adherence to HIV therapies: Critical issues. *Science to Community, Clinical #1*. University of California-San Francisco, San Francisco, California.
- Broers, B., Morabia, A., Hirschel, B. (1994). A cohort study of drug users' compliance with zidovudine treatment. *Archives of Internal Medicine*, 154(10), 1121-1127.
- Beauverie, P., Taburet, A. M., Dessalles, M. C., et al. (1998). Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. *AIDS*, 12(18), 2510-2511.
- Bruno, R., Sacchi, P., Puoti, M., et al. (2002). HCV chronic hepatitis in patients with HIV: Clinical management issues. *American Journal of Gastroenterology*, 97(7), 1598-1606.
- Carmona, A., Knobel, H., Guelar, A., et al. (2000). Factors influencing survival in HIV-infected patients treated with HAART [Abstract TuOrB417]. Presented at 13<sup>th</sup> International AIDS Conference, Durban, South Africa, July 9-14, 2000.
- Cedars-Sinai Medical Center. (2001). *Adherence Now: Best Practices and Practical Tools. Proceedings of a roundtable symposium in November 2001*. World Heath CME, New York, New York.
- Centers for Disease Control and Prevention. (2002). Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: Recommendations of the Panel on Clinical Practices for Treatment of HIV. *MMWR*, 51(RR-7), 1-55.  
(<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5107a1.htm>)

Centers for Disease Control and Prevention. (1998). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. *MMWR*, 47(RR-20), 1-58.  
[\(http://www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm\)](http://www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm)

Chesney, M.A. Factors affecting adherence to antiretroviral therapy. (2000). *Clinical Infectious Diseases*, 30(Suppl 2), 171-176.

Chesney, M. (January 1999). The challenge of adherence. *Bulletin of Experimental Treatments for AIDS* 12(1), 10-13.  
[\(http://www.saf.org/treatment/beta/b39/b39adhere.html\)](http://www.saf.org/treatment/beta/b39/b39adhere.html)

Clarke S., Mulcahy F., Bergin C., et al. (2002). Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. *Clinical Infectious Diseases*, 34(8), 1143-1145.

Clarke, S., Mulcahy, F., Tija, J., et al. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. *British Journal of Clinical Pharmacology*, 51(3), 213-217.

Eldin, B.R., Seal, K., Lorwick, J., et al. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit injection drug users? *New England Journal of Medicine*, 345(3), 211-214.

Elliot, A. Depression and HIV. (1997). Retrieved December 2002 at the Project Inform website at <http://www.projectinform.org>.

Ferrando, S.J. (2001). Substance abuse and HIV infection. *Psychiatric Annals*, 31(1), 57-62.

Fried, M.W., Schiffman, M.L., Reddy, K.R., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *New Journal of Medicine*, 347(13), 975-982.

Gordillo V., del Amo, J., Soriano, V., et al. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. *AIDS*, 13(13), 1763-1769.

Golin, C.E., Liu, H., Hays, R.D., et al. (2002). A prospective study of predictors of adherence to combination antiretroviral medication. *Journal of General Internal Medicine*, 17(11), 756-765.

Gourevitch, M.N., Friedland, G.H. (2000). Interactions between methadone and medications used to treat HIV infection: A review. *Mount Sinai Journal of Medicine*, 67(5-6), 429-436.

Henry, J.A., Hill, I.R. (1998). Fatal interaction between ritonavir and MDMA. *Lancet*, 352(9142), 1751-1752.

Harrington, R.D., Woodward, J.A., Hooton, T.M., et al. (1999). Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and  $\gamma$ -hydroxybutyrate. *Archives of Internal Medicine*, 159(18), 2221-2224.

Horn, G. (1998). Party favors – Do yourself one: Get the dope on the protease effect. *POZ*, 36. Available on the *POZ* web site at <http://www.poz.com/archive/june1998/partner/warning.html>

Horn, T. (2001). HIV drug resistance and drug resistance testing: Just the FAQ's. *CRIA Update*, 10(4).

Landau, A., Batisse, D., Piketty, C., et al. (2001). Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. *AIDS*, 15(16), 2149-2155.

Lauer, G.M., Walker, B.D. (2001). Hepatitis C virus infection. *New England Journal of Medicine*, 345(1), 41-51.

McCance-Katz, E.F., Rainey, P.M., Jatlow, P., et al. (1998). Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). *Journal of Acquired Immune Deficiency Syndrome Human Retrovirology*, 18(5), 435-443.

Murphy, E.L., Collier, A.C., Kalish, L.A., et al. (2001). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. *Annals of Internal Medicine*, 135(1), 17-26.

Nasti, G., DiGennaro, G., Tavio, M., et al. (2001). Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. *AIDS*, 15(14), 1783-1787.

O'Connor, P.G., Selwyn, P.A., Schottenfeld, R.S. (1994). Medical progress: Medical care for injection-drug users with human immunodeficiency virus infection. *New England Journal of Medicine*. 331(7), 450-459.

Paterson, D.L., Swindells, S., Mohr, J., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Annals of Internal Medicine*, 133(1), 21-30.

Peterson, P.K., Gekker, G., Chao, C.C., et al. (1991). Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. *Journal of Immunology*, 146(1), 81-84.

Peterson, P.K., Gekker, G., Chun, C.C., et al. (1992). Cocaine amplifies HIV-1 replication in cytomegalovirus-stimulated peripheral blood mononuclear cell cocultures. *Journal of Immunology*, 149(2), 676-680.

Project Inform. (May 1996). Building a cooperative doctor/patient relationship. Retrieved December 2002 at the Project Inform website  
<http://www.projectinform.org/pdf/doctorpatient.pdf>.

Rainey, P.M., Friedland, G., McCance-Katz, E.F., et al. (2000). Interaction of methadone with didanosine and stavudine. *Journal of AIDS*, 24(3), 241-248.

Reiter, G.S., Stewart, K.E., Wojtusik, L., Hewitt, R., Segal-Maurer, S., Johnson, M., et al. (2000). Elements of success in HIV clinical care: Multiple interventions that promote adherence. *Topics in HIV Medicine*. 8(5), 21-30.

Richman, D. D., Bozette, S., Morton, S., Chien, S., Wrin, T., Dawson, K., Hellmann, N. "The Prevalence of Antiretrviral Drug Resistance in the U.S." (Abstract LB-17), 41st Intersceince Conference on Antimicrobial Agents and Chemotherapy, 2001.

Roth, M.D., Tashkin, D.P., Choi, R., et al. (2002). Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. *Journal of Infectious Diseases*, 185(5), 701-705.

Samet, J.H., Libman, H., Steger, K.A., et al. (1992). Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic. *American Journal of Medicine*, 92(5), 495-502.

Selwyn, P.A., Hartel, D., Lewis, V.A., et al. (1989). A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *New England Journal of Medicine*, 320(9), 545-550.

Selwyn, P.A., Feingold, A.R., Hartel, D., et al. (1988). Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. *AIDS*, 2(4), 267-272.

Shapiro, M.F., Morton, S.C., McCaffrey, D.F., et al. (1999). Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. *JAMA*, 281(24), 2305-2315.

Sherer, R. (1998). Adherence and antiretroviral therapy in injection drug users. *JAMA*, 280(6), 567-568.

Soto, B., Sanchez-Quijano, A., Rodrigo, L., et al. (1997). Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *Journal of Hepatology*, 26(1), 1-5.

Strathdee, S.A., Palepu, A., Cornelisse, P.G., et al. (1998). Barriers to use of free antiretroviral therapy in injection drug users. *JAMA*, 280(6), 547-549.

Staszewski, S., Haberl, A., Gute, P., et al. (1998). Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. *Antiviral Therapy*, 3(Suppl 4), 55-56.

Stein, J.A., Gelberg L. (1997). Comparability and representativeness of clinical homeless, community homeless, and domiciled clinic samples: Physical and mental health, substance use, and health services utilization. *Health Psychology*, 16(2), 155-162.

Stone, V.E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. *Clinical Infectious Diseases*, 33(6), 865-872.

Walsh, J.C., Hertogs, K., Gazzard, B. (2000). Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor (PI) based highly active antiretroviral therapy (HAART) [Abstract 699]. Presented at the 40<sup>th</sup> Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000, 294.

Whalen, C., Horsburgh, C.R., Hom, D., et al. (1995). Accelerated course of human immunodeficiency virus infection after tuberculosis. *American Journal of Respiratory Critical Care Medicine*, 151(1), 129-135.

Williams, A., Friedland, G. (1997). Adherence, compliance, and HAART. *AIDS Clinical Care*, 9(7), 51-54, 58.

## Lecture List

University of California San Francisco. (2002). *Addressing the challenges of adherence. Navigating emerging challenges to long-term HIV therapy.* World Heath CME, New York, New York.

Chesney, M.A. Factors affecting adherence to antiretroviral therapy. (2000). *Clinical Infectious Diseases*, 30(Suppl 2), 171-176.

Chesney, M. (January 1999). The challenge of adherence. *Bulletin of Experimental Treatments for AIDS* 12(1), 10-13.  
[\(http://www.saf.org/treatment/beta/b39/b39adhere.html\)](http://www.saf.org/treatment/beta/b39/b39adhere.html)

O'Connor, P.G., Selwyn, P.A., Schottenfeld, R.S. (1994). Medical progress: Medical care for injection-drug users with human immunodeficiency virus infection. *New England Journal of Medicine*. 331(7), 450-459.

Project Inform. (October 2002). Adherence: Keeping up with your meds. Retrieved December 2002 from the Project Inform website at <http://www.projectinform.org/pdf/adherence.pdf>.

Project Inform. (May 1996). Building a cooperative doctor/patient relationship. Retrieved December 2002 from the Project Inform website at <http://www.projectinform.org/pdf/doctorpatient.pdf>